Global perspective on pediatric growth hormone registries: a systematic review
- 20 April 2022
- journal article
- review article
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 35 (6), 709-726
- https://doi.org/10.1515/jpem-2022-0045
Abstract
Objectives Registries are considered valuable data sources for identification of pediatric conditions treated with growth hormone (GH), and their follow-up. Currently, there is no systematic literature review on the scope and characteristics of pediatric GH registries. Therefore, the purpose of this systematic review is to identify worldwide registries reported on pediatric GH treatment and to provide a summary of their main characteristics. Content Pediatric GH registries were identified through a systematic literature review. The search was performed on all related literature published up to January 30th, 2021. Basic information on pediatric GH registries, their type and scope, purpose, sources of data, target conditions, reported outcomes, and important variables were analyzed and presented. Summary Twenty two articles, reporting on 20 pediatric GH registries, were included in this review. Industrial funding was the most common funding source. The main target conditions included in the pediatric GH registries were: growth hormone deficiency, Turner syndrome, Prader Willi syndrome, small for gestational age, idiopathic short stature, and chronic renal insufficiency. The main objectives in establishing and running pediatric GH registries were assessing the safety and effectiveness of the treatment, describing the epidemiological aspects of target growth conditions and populations, serving public health surveillance, predicting and measuring treatment outcomes, exploring new and useful aspects of GH treatment, and improving the quality of patient care. Outlook This systematic review provides a global perspective on pediatric GH registries which can be used as a basis for the design and development of new GH registry systems at both national and international levels.Keywords
This publication has 58 references indexed in Scilit:
- A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndromeActa Endocrinologica, 2013
- The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)Clinical Epidemiology, 2013
- Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® in children requiring growth hormone treatmentTherapeutic Advances in Endocrinology and Metabolism, 2013
- Japanese growth prediction model for prepubertal children with growth hormone deficiencyJournal of Pediatric Endocrinology and Metabolism, 2012
- Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®International Journal of Pediatric Endocrinology, 2011
- Prediction models for short children born small for gestational age (SGA) covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database)BMC Medical Informatics and Decision Making, 2011
- History of growth hormone therapyIndian Journal of Endocrinology and Metabolism, 2011
- Registration of observational studies: Is it time?CMAJ : Canadian Medical Association Journal, 2010
- Growth hormone measurements versus auxology in treatment decisions: The Australian experienceThe Journal of Pediatrics, 1996